-$1.35 Earnings Per Share Expected for Atara Biotherapeutics Inc (NASDAQ:ATRA) This Quarter

Equities analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings per share (EPS) of ($1.35) for the current quarter, according to Zacks. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.38) to ($1.31). Atara Biotherapeutics posted earnings per share of ($1.60) in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.6%. The firm is scheduled to issue its next earnings results on Thursday, August 13th.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.63) per share for the current financial year, with EPS estimates ranging from ($5.34) to ($4.14). For the next year, analysts expect that the business will post earnings of ($4.35) per share, with EPS estimates ranging from ($5.29) to ($3.26). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.21.

ATRA has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price objective on Atara Biotherapeutics from $22.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Zacks Investment Research raised Atara Biotherapeutics from a “hold” rating to a “buy” rating and set a $9.50 target price on the stock in a report on Thursday, May 7th. Evercore ISI started coverage on Atara Biotherapeutics in a report on Tuesday. They issued an “outperform” rating on the stock. HC Wainwright started coverage on Atara Biotherapeutics in a report on Monday, June 15th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $26.95.

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 12,135 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $12.92, for a total transaction of $156,784.20. Following the transaction, the chief executive officer now owns 264,844 shares of the company’s stock, valued at $3,421,784.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.

Several hedge funds have recently modified their holdings of the business. Redmile Group LLC boosted its stake in shares of Atara Biotherapeutics by 13.9% during the first quarter. Redmile Group LLC now owns 5,293,370 shares of the biotechnology company’s stock worth $45,047,000 after buying an additional 644,800 shares during the period. Maverick Capital Ltd. boosted its stake in shares of Atara Biotherapeutics by 4.9% during the first quarter. Maverick Capital Ltd. now owns 5,199,897 shares of the biotechnology company’s stock worth $44,251,000 after buying an additional 241,466 shares during the period. Morgan Stanley boosted its stake in shares of Atara Biotherapeutics by 18.1% during the first quarter. Morgan Stanley now owns 3,462,329 shares of the biotechnology company’s stock worth $29,463,000 after buying an additional 529,482 shares during the period. Bridger Management LLC boosted its stake in shares of Atara Biotherapeutics by 10.2% during the fourth quarter. Bridger Management LLC now owns 2,932,865 shares of the biotechnology company’s stock worth $48,304,000 after buying an additional 271,845 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Atara Biotherapeutics by 26.5% during the first quarter. Federated Hermes Inc. now owns 2,889,541 shares of the biotechnology company’s stock worth $24,590,000 after buying an additional 605,068 shares during the period.

Shares of NASDAQ ATRA traded up $0.32 during mid-day trading on Tuesday, hitting $13.84. The company had a trading volume of 1,999,800 shares, compared to its average volume of 1,185,467. The company has a market capitalization of $797.03 million, a PE ratio of -2.53 and a beta of 2.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.27 and a quick ratio of 7.27. Atara Biotherapeutics has a 1-year low of $4.52 and a 1-year high of $21.45. The business’s 50-day simple moving average is $11.38 and its 200 day simple moving average is $11.92.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: What is a resistance level?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.